1-6 of 6
Robert M. Sharkey
Close
Sort by
Journal Articles

A New Antibody-Drug Conjugate Composed of an Anti-HLA-DR IgG4 Antibody, IMMU-114, and SN-38, Is Active in Experimental Acute Myelocytic Leukemia (AML), Acute Lymphocytic Leukemia (ALL), and Multiple Myeloma (MM)

David M Goldenberg, ScD, MD, Robert M Sharkey, Ph.D., Serengulam V Govindan, PhD, Maria Zalath, BA, Ali Mostafa, BS, Thomas M Cardillo, Ph.D.
Journal: Blood
Blood (2016) 128 (22): 3958.
https://doi.org/10.1182/blood.V128.22.3958.3958
Published: 2016
Journal Articles

Combination Therapy Targeting Two Different Antigens with Anti-CD22 Radioimmunotherapy and Anti-CD20 Immunotherapy in Non-Hodgkin Lymphoma (NHL): Phase I Results

Michael B Tomblyn, MD, MS, Thomas E. Witzig, MD, Andrew L Himelstein, MD, Rebecca Elstrom, MD, Ebenezer A Kio, MD, Robert M Sharkey, PhD, Jonathan Rojo, MD, William Wegener, MD, PhD, David M Goldenberg, ScD, MD
Journal: Blood
Blood (2012) 120 (21): 3680.
https://doi.org/10.1182/blood.V120.21.3680.3680
Published: 2012
Journal Articles

Epratuzumab (Humanized Anti-CD22 MAb) Conjugated with SN-38, a New Antibody-Drug Conjugate (ADC) for the Treatment of Hematologic Tumors: Preclinical Studies Alone and In Combination with Veltuzumab, a Humanized Anti-CD20 MAb

David M Goldenberg, Sc.D., M.D., Serengulam Govindan, Ph.D., Tom M Cardillo, Ph.D., Robert M Sharkey, Ph.D.
Journal: Blood
Blood (2010) 116 (21): 3941.
https://doi.org/10.1182/blood.V116.21.3941.3941
Published: 2010
Journal Articles

A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy

Robert M. Sharkey, Oliver W. Press, David M. Goldenberg
Journal: Blood
Blood (2009) 113 (17): 3891–3895.
https://doi.org/10.1182/blood-2008-11-188896
Published: 2009
Journal Articles

Radioimmunotherapy of Non-Hodgkin Lymphoma is Improved without Increasing Toxicity by Combination with Antibody immunotherapy.

Robert M Sharkey, Ph.D., M. Jules Mattes, Ph.D., Habibe Karacay, Ph.D., Chien-Hsing Chang, PhD, Edmund A Rossi, PhD, William J McBride, Ph.D., David M. Goldenberg, ScD, MD
Journal: Blood
Blood (2008) 112 (11): 1588.
https://doi.org/10.1182/blood.V112.11.1588.1588
Published: 2008
Journal Articles

Improved Responses and Cures with Less Hematologic Toxicity Using Anti-CD20 Bispecific Antibody Pretargeted Radionuclides Compared to Directly Radiolabeled IgG in a NHL Model.

David M. Goldenberg, ScD, MD, Robert M. Sharkey, PhD, Habibe Karacay, PhD, Chien-Hsing Chang, PhD, Edmund A. Rossi, PhD, William J. McBride, PhD
Journal: Blood
Blood (2007) 110 (11): 2344.
https://doi.org/10.1182/blood.V110.11.2344.2344
Published: 2007